National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

| Items in cart [0]

The National Academies Press

PAPERBACK
price:$43.50
add to cart

Rights & Permissions

topleft topright

New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries (1986)
Board on Population Health and Public Health Practice (BPH)

Citation Manager

. "Appendix D-7: The Prospects for Immunizing Against Mycobacterium leprae." New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press, 1986.

Please select a format:

BibTeX EndNote RefMan


Page
250
bottomleft bottomright

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.


New Vaccine Development: Establishing Priorities, Volume II, Diseases of Importance in Developing Countries

Abstracts of the 12th International Leprosy Congress, New Delhi, India. Session II, No. 54.

Sansarricq, H. 1981. Leprosy in the world today. Lepr. Rev. 52(suppl. 1):15–31.

Sansarricq, H. 1982. The Kellersberger Memorial Lecture, 1981: the general situation of leprosy in the world. Ethiop. Med. J. 20:89–106.

Shepard, C.C. 1983. Animal vaccine studies with Mycobacterium leprae. Int. J. Leprosy 51:519–523.

Shepard, C.C., and D.H.McRae. 1965. Mycobacterium leprae in mice: Minimal infectious dose, relationship between staining quality and infectivity and effect of cortisone. J. Bacteriol. 89:365–372.

Shepard, C.C., L.I.Walker, and R.Van Landingham. 1978. Heat stability of Mycobacterium leprae immunogenicity. Infect. Immun. 22:87–93.

SPRTTD (Special Programme for Research and Training in Tropical Diseases). 1983. Primary resistance to dapsone among untreated patients in Bamako and Chingleput. Report of the Subcommittee on Clinical Trials, Scientific Working Group on the Chemotherapy of Leprosy (THELEP). Leprosy Rev. 54:177–183.

SPRTTD (Special Programme for Research and Training in Tropical Diseases). 1985. Leprosy. Pp. 8/1–8/19 in Tropical Disease Research. Seventh Programme Report, 1 January 1983–31 December 1984. Geneva: World Health Organization.


Talwar, G.P., and A.Fotedar. 1983. Two candidate antileprosy vaccines—current status of their development. Int. J. Lepr. 51:550–552.


Wolf, R.H., B.J.Gormus, L.N.Martin, G.B.Baskin, G.P.Walsh, W.M. Meyers, and C.H.Binford. 1985. Experimental leprosy in three species of monkeys. Science 227:529–531.


Young, R.A., V.Mehra, D.Sweetser, T.Buchanan, J.Clark-Curtis, R.W.Davis, and B.R.Bloom. 1985. Genes for the major antigens of the parasite causing leprosy. Nature 316:450–452.

Page
250
Front Matter (R1-R16)
1. Summary (1-18)
2. Priority Setting for Health-Related Investments: A Review of Methods (19-29)
3. Overview of the Analytic Approach (30-43)
4. Comparison of Disease Burdens (44-62)
5. Predictions of Vaccine Development (63-75)
6. Assessing the Likely Utilization of New Vaccines (76-81)
7. Calculation and Comparison of the Health Benefits and Differential Costs Associated with Candidate Vaccines (82-105)
8. Additional Issues in the Selection of Priorities for Accelerated Vaccine Development (106-120)
9. Findings, Conclusions, and Recommendations (121-142)
Appendix A: Selection of Vaccine Candidates for Accelerated Development (143-148)
Appendix B: The Burden of Disease Resulting from Acute Respiratory Illness (149-158)
Appendix C: The Burden of Disease Resulting from Diarrhea (159-169)
Appendix D-1: The Prospects for Immunizing Against Dengue Virus (170-177)
Appendix D-2: The Prospects for Immunizing Against Escherichia coli (178-185)
Appendix D-3: The Prospects for Immunizing Against Hemophilus influenzae Type b (186-196)
Appendix D-4: The Prospects for Immunizing Against Hepatitis A Virus (197-207)
Appendix D-5: The Prospects for Immunizing Against Hepatitis B Virus (208-222)
Appendix D-6: The Prospects for Immunizing Against Japanese Encephalitis Virus (223-240)
Appendix D-7: The Prospects for Immunizing Against Mycobacterium leprae (241-250)
Appendix D-8: The Prospects for Immunizing Against Neisseria meningitidis (251-266)
Appendix D-9: The Prospects for Immunizing Against Parainfluenza Viruses (267-274)
Appendix D-10: The Prospects for Immunizing Against Plasmodium spp. (275-286)
Appendix D-11: The Prospects for Immunizing Against Rabies Virus (287-298)
Appendix D-12: The Prospects for Immunizing Against Respiratory Syncytial Virus (299-307)
Appendix D-13: The Prospects for Immunizing Against Rotavirus (308-318)
Appendix D-14: The Prospects for Immunizing Against Salmonella typhi (319-328)
Appendix D-15: The Prospects for Immunizing Against Shigella spp. (329-337)
Appendix D-16: The Prospects for Immunizing Against Streptococcus Group A (338-356)
Appendix D-17: The Prospects for Immunizing Against Streptococcus pneumoniae (357-375)
Appendix D-18: The Prospects for Immunizing Against Vibrio cholerae (376-389)
Appendix D-19: The Prospects for Immunizing Against Yellow Fever (390-402)
Appendix E: Questionnaire for Assessing Morbidity-Mortality Trade-Offs (403-411)
Appendix F: Technical Notes (412-412)
Appendix G: Biographical Notes on Committee Members (413-417)
Appendix H: Additional Sources of Advice to the Committee (418-419)
Appendix I: Contents of Supplement to Volume II (420-420)
Appendix J: Preface to Volume I (421-422)
Appendix K: Contents to Volume I (423-423)
Index (424-432)